Pavmed Stock Price, News & Analysis

PAVmed (Nasdaq: PAVM), a diversified commercial-stage medical technology company, has scheduled a business update conference call and webcast for August 14, 2025, at 8:30 AM ET. During the call, Chairman and CEO Dr. Lishan Aklog will discuss company operations and growth strategy, while President and CFO Dennis McGrath will present Q2 2025 financial results.

Investors can access the webcast through PAVmed's investor relations website. For telephone access, U.S. callers should dial 1-800-836-8184, while international callers can use 1-646-357-8785. A 30-day replay will be available on the company website following the call.

Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), will host a business update conference call on August 13, 2025, at 8:30 AM ET.

The call will feature CEO Lishan Aklog discussing business operations and growth strategy, while CFO Dennis McGrath will present Q2 2025 financial results. Investors can access the webcast through luciddx.com or join by phone using specific dial-in numbers for U.S. and international callers.

PAVmed (Nasdaq: PAVM), a commercial-stage medical technology company, has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. The company now has until January 19, 2026 to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days.

The notification does not immediately affect PAVmed's listing status, and its shares will continue trading on the Nasdaq Capital Market under the symbol "PAVM". The company has stated its intention to take appropriate actions to cure the deficiency and regain compliance before the extended deadline.

Lucid Diagnostics (NASDAQ:LUCD) announced that MolDX-participating Medicare Administrative Contractors will hold a critical Contractor Advisory Committee (CAC) meeting on September 4, 2025 to evaluate Medicare coverage for its EsoGuard® Esophageal DNA Test.

The virtual meeting will gather medical experts to reconsider Local Coverage Determination (LCD) L39256, following Lucid's November 2024 request. CEO Lishan Aklog highlighted the company's strong clinical evidence package and noted that nearly 40,000 patients have been referred for EsoGuard testing to date. The test's clinical utility is supported by professional society guidelines and peer-reviewed publications.

PAVmed (Nasdaq: PAVM) announced that its subsidiary Veris Health has completed a $2.5 million private placement equity financing. The financing involved selling Veris Health common stock at $1.40 per share, with a pre-money valuation of $35 million.

Investors received warrants to purchase additional shares at $1.40 per share, callable within 60 days of FDA clearance. This funding follows a previous $2.4 million financing earlier this year. The proceeds will support the development of Veris' implantable physiological monitor through FDA clearance, expected in 2026, and general corporate purposes.

Lucid Diagnostics (LUCD) has partnered with Hoag, a major California healthcare network, to implement EsoGuard® Esophageal DNA Test across its healthcare system. The partnership aims to expand access to esophageal precancer testing through Hoag's digestive health, primary care, and concierge medicine programs. Dr. Kenneth Chang, Executive Medical Director at Hoag's Digestive Health Institute, emphasized the importance of this initiative, noting that esophageal cancer incidence has increased tenfold over four decades. EsoGuard offers a quick, 3-minute non-endoscopic test to identify at-risk patients. Lucid's CEO, Dr. Lishan Aklog, views this collaboration as a significant milestone in expanding EsoGuard's accessibility within large healthcare systems and expects it to serve as a model for future partnerships.

PAVmed's subsidiary Veris Health has established a strategic partnership with The Ohio State University Comprehensive Cancer Center (OSUCCC - James) following a successful pilot program. The partnership involves expanding the commercial use of the Veris Cancer Care Platform, which includes remote physiological monitoring, symptom reporting, and telehealth capabilities. The agreement encompasses full EHR integration, a clinical registry launch, and plans for a clinical trial of an implantable physiologic monitor pending FDA clearance. The platform utilizes VerisBox, containing connected healthcare devices that transmit data to a cloud-based portal, while patients can report symptoms through a smartphone app. This partnership with one of the nation's largest academic cancer centers marks a significant milestone for Veris in enhancing personalized cancer care delivery.

Lucid Diagnostics (NASDAQ: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (NASDAQ: PAVM), announced its upcoming inclusion in both the Russell 2000® Index and Russell 3000® Index. The inclusion will be effective after market close on June 27, 2025, as part of the annual reconstitution. The Russell 3000 Index comprises the largest 3,000 U.S. public companies by market cap, while the Russell 2000 focuses on small-cap companies. According to FTSE Russell, approximately $10.6 trillion in assets are benchmarked against Russell U.S. Indexes, which are widely used by investment managers and institutional investors.

PAVmed (NASDAQ: PAVM) reported its Q1 2025 financial results and business updates. The company's subsidiary Lucid Diagnostics strengthened its position with $30.6M in stock offerings, ending Q1 with over $40M in proforma cash. Lucid processed 3,034 EsoGuard tests, generating $0.8M in revenue. Veris Health completed financing and resumed development of its implantable physiological monitor, preparing to launch a partnership with a major cancer center. PAVmed reported GAAP net income of $17.7M ($0.34 per share) and non-GAAP adjusted loss of $0.9M (-$0.07 per share). The company ended Q1 with $2.7M in cash, up from $1.2M in December 2024. PAVmed is now exploring expansion into the biopharma sector, actively evaluating clinical and late preclinical-stage assets.